What PTAB Markush Rejection Means For Biotech Applicants

Law360, New York (March 16, 2017, 12:19 PM EDT) -- Jeff B. Vockrodt

Christopher H. Yaen The Patent Trial and Appeal Board for the first time in many years affirmed an examiner's rejection of a claim as an "improper Markush" in Ex parte Chettier.[1] Patent examiners have increasingly turned to "Markush rejections"[2] in the wake of the U.S. patent and Trademark Office's 2011 guidelines on the subject.[3] This controversial practice attempts to force patent applicants to narrow their claimed genus or other Markush-type group even when those claims meet all other conditions for patentability such as novelty, nonobviousness, and enablement, for example. The board's focus on lack of common core structure...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!